Key Highlights
- SEQSTER and Antidote Technologies partner to enhance patient identification for clinical trials.
- Integration of SEQSTER’s Operating System provides a 360° view of patient data.
- Improved trial timelines and enrollment outcomes for Pharma and Life Science companies.
- Increased diversity in clinical trials by addressing barriers for underserved populations.
- Enhanced patient engagement and adherence through personalized support services.
Source: Business Wire
Notable Quotes
- “By integrating SEQSTER’s Operating System with Antidote’s precision recruitment capabilities, we are creating a powerful synergy that addresses one of the most pressing challenges in clinical research today: clinical trial recruitment plus engagement. This partnership empowers us to accelerate patient recruitment while providing a comprehensive, real-time view of study participant health data, accelerating the path to medical breakthroughs.” — Ardy Arianpour, CEO & Co-Founder at SEQSTER
- “Our mission at Antidote has always been to connect the right patients with the right trials, striking a balance between advanced technology and a personal touch. Partnering with SEQSTER allows us to enhance our precision recruitment process with unparalleled data integration capabilities, ensuring that we can more effectively identify suitable participants and reduce the time it takes to bring new treatments to market. Together with SEQSTER, we will transform the clinical trial landscape, making it more efficient, inclusive, and patient-centered.” — Samantha Veeck, Co-CEO at Antidote
SoHC's Take
The partnership between SEQSTER and Antidote Technologies marks a significant advancement in clinical trial recruitment and patient engagement. By leveraging SEQSTER’s comprehensive data integration capabilities and Antidote’s extensive patient support services, this collaboration addresses critical challenges in the clinical research field. The integration facilitates a more accurate and efficient matching of patients to clinical trials, ensuring faster recruitment and improved quality of participant data. Furthermore, this partnership plays a crucial role in promoting diversity within clinical trials, which is essential for the generalizability of research findings and compliance with FDA requirements. Overall, this synergy has the potential to expedite medical breakthroughs and improve healthcare outcomes on a broad scale.
